(R)-3-(4-((4-methoxyphenyl)((4-methylpyridin-3-yl)methyl)amino)piperidin-1-yl)butanenitrile | 1350809-30-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (R)-3-(4-((4-methoxyphenyl)((4-methylpyridin-3-yl)methyl)amino)piperidin-1-yl)butanenitrile
• CAS: 1350809-30-1
• 化学式: C₂₃H₃₀N₄O
• 分子量: 378.517
• InChiKey: CUQWIZXURVEGIQ-LJQANCHMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.17
• 重原子数：
  28.0
• 可旋转键数：
  7.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  52.39
• 氢给体数：
  0.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  (R)-3-(4-((4-methoxyphenyl)((4-methylpyridin-3-yl)methyl)amino)piperidin-1-yl)butanenitrile 在 硼烷四氢呋喃络合物 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 6-Chloro-N-((R)-3-{4-[(4-methoxy-phenyl)-(4-methyl-pyridin-3-ylmethyl)-amino]-piperidin-1-yl}-butyl)-2,4-dimethyl-nicotinamide
  参考文献：
  名称：

  Design and synthesis of pyridin-2-ylmethylaminopiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication

  摘要：

  A series of CCR5 antagonists were optimized for potent inhibition of R5 HIV-1 replication in peripheral blood mononuclear cells. Compounds that met acceptable ADME criteria, selectivity, human plasma protein binding, potency shift in the presence of alpha-glycoprotein were evaluated in rat and dog pharmacokinetics. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.09.133
• 作为产物：
  描述：

  (R)-3-(4-oxopiperidin-1-yl)butyronitrile 在 三乙酰氧基硼氢化钠 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 (R)-3-(4-((4-methoxyphenyl)((4-methylpyridin-3-yl)methyl)amino)piperidin-1-yl)butanenitrile
  参考文献：
  名称：

  Design and synthesis of pyridin-2-ylmethylaminopiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication

  摘要：

  A series of CCR5 antagonists were optimized for potent inhibition of R5 HIV-1 replication in peripheral blood mononuclear cells. Compounds that met acceptable ADME criteria, selectivity, human plasma protein binding, potency shift in the presence of alpha-glycoprotein were evaluated in rat and dog pharmacokinetics. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.09.133